Related references
Note: Only part of the references are listed.Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2021)
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
Francesco Paolo Tambaro et al.
LEUKEMIA (2021)
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia
Allison J. Kaeding et al.
BLOOD ADVANCES (2021)
Poster: AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
David Sallman et al.
Clinical Lymphoma Myeloma & Leukemia (2021)
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation
Keith W. Pratz et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J. Roboz et al.
BLOOD (2020)
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
Elise Fournier et al.
BLOOD (2020)
Checkpoint inhibitors in AML: are we there yet?
Arnab Ghosh et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
The genomics of acute myeloid leukemia in children
Shannon E. Conneely et al.
CANCER AND METASTASIS REVIEWS (2020)
Targeting RAS in pediatric cancer: is it becoming a reality?
Angelina V. Vaseva et al.
CURRENT OPINION IN PEDIATRICS (2020)
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
Szymon Klossowski et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao et al.
FRONTIERS IN ONCOLOGY (2020)
Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial
Andrew H. Wei et al.
BLOOD (2020)
Targeting AML-associated FLT3 mutations with a type I kinase inhibitor
LaQuita M. Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study
Seth E. Karol et al.
LANCET ONCOLOGY (2020)
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN)
Andreas Burchert et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial
Li Xuan et al.
LANCET ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Andrew. D. J. Pearson et al.
EUROPEAN JOURNAL OF CANCER (2020)
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Amy Burd et al.
NATURE MEDICINE (2020)
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
Vanessa E. Kennedy et al.
FRONTIERS IN ONCOLOGY (2020)
Results of a Phase 2, Randomized, Double-Blind Study of Sorafenib Versus Placebo in Combination with Intensive Chemotherapy in Previously Untreated Patients with FLT3-ITD Acute Myeloid Leukemia (ALLG AMLM16)
Andrew H. Wei et al.
BLOOD (2020)
Characteristics and Prognostic Effects of IDH Mutations across the Age Spectrum in AML: A Collaborative Analysis from COG, SWOG, and ECOG
Sara Zarnegar-Lumley et al.
BLOOD (2020)
Target-Informed Repurposing of Immunotherapies in AML - a Transcriptome Based Approach for Identifying Immediately Available Therapeutics
Amanda R. Leonti et al.
BLOOD (2020)
Panel-based next-generation sequencing facilitates the characterization of childhood acute myeloid leukemia in clinical settings
Hisashi Ishida et al.
BIOMEDICAL REPORTS (2020)
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801
Guido Marcucci et al.
BLOOD ADVANCES (2020)
Gilteritinib: potent targeting of FLT3 mutations in AML
Mark Levis et al.
BLOOD ADVANCES (2020)
New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
Jing Chen et al.
CHILDREN-BASEL (2020)
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
Juliette Lambert et al.
HAEMATOLOGICA (2019)
Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Charlotte M. Niemeyer et al.
BLOOD (2019)
Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
Ross L. Levine et al.
HAEMATOLOGICA (2019)
Preclinical Evaluation of Bispecific Adaptor Molecule Controlled Folate Receptor CAR-T Cell Therapy With Special Focus on Pediatric Malignancies
Yingjuan J. Lu et al.
FRONTIERS IN ONCOLOGY (2019)
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
Danielle Golub et al.
FRONTIERS IN ONCOLOGY (2019)
Hedgehog signaling inhibitors in solid and hematological cancers
Jorge E. Cortes et al.
CANCER TREATMENT REVIEWS (2019)
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia
Katherine Tarlock et al.
CLINICAL CANCER RESEARCH (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant
Aude G. Chapuis et al.
NATURE MEDICINE (2019)
V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia
Laura Agresta et al.
BLOOD (2019)
Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention
Thomas Mercher et al.
FRONTIERS IN PEDIATRICS (2019)
Targeted Therapies for Pediatric AML: Gaps and Perspective
Annalisa Lonetti et al.
FRONTIERS IN PEDIATRICS (2019)
Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
Eytan M. Stein et al.
BLOOD (2019)
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD
Richard F. Schlenk et al.
BLOOD (2019)
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Yuxin Liu et al.
BLOOD REVIEWS (2019)
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
Abhishek Maiti et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myelodysplasies (GFM)
Thomas Cluzeau et al.
BLOOD (2019)
Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031
Jessica A. Pollard et al.
BLOOD (2019)
Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Adam J. Lamble et al.
BLOOD (2019)
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
Andrei V. Krivtsov et al.
CANCER CELL (2019)
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
Dyantha van der Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
Jorge E. Cortes et al.
LEUKEMIA (2019)
Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia
Jarno L. Kivioja et al.
LEUKEMIA (2019)
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia
Diogo Gomes-Silva et al.
MOLECULAR THERAPY (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG plus AML
Sun Yao et al.
FRONTIERS IN ONCOLOGY (2019)
Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
Malte Roerden et al.
FRONTIERS IN IMMUNOLOGY (2019)
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
Nicholas J. Short et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2019)
Venetoclax for AML: changing the treatment paradigm
Daniel A. Pollyea et al.
BLOOD ADVANCES (2019)
KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia
Xi Chen et al.
LEUKEMIA & LYMPHOMA (2018)
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
Hamid Bolouri et al.
NATURE MEDICINE (2018)
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
Eytan M. Stein et al.
BLOOD (2018)
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
Rajeswaran Mani et al.
HAEMATOLOGICA (2018)
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Ying Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Jinghua Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012
Mareike Rasche et al.
LEUKEMIA (2018)
Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial
Peter Paschka et al.
LEUKEMIA (2018)
Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
Kerstin M. Kampa-Schittenhelm et al.
Oncotarget (2018)
Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling
Katherine Tarlock et al.
Oncotarget (2018)
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors
Rajeswaran Mani et al.
HAEMATOLOGICA (2018)
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML
Amir T. Fathi et al.
BLOOD (2018)
A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells
Yelena Kovtun et al.
BLOOD ADVANCES (2018)
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Farhad Ravandi et al.
BLOOD (2018)
First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial
Fang Liu et al.
BLOOD (2018)
A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
Naval G. Daver et al.
BLOOD (2018)
Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse
Robson G. Dossa et al.
BLOOD (2018)
A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2018)
Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia
C. Dafflon et al.
LEUKEMIA (2017)
NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis
S. Struski et al.
LEUKEMIA (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions
Maria Larrosa-Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
Daniel B. Lipka et al.
NATURE COMMUNICATIONS (2017)
Found in Translation : How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Joel D. Leverson et al.
CANCER DISCOVERY (2017)
Clinical Impact of Genomic Information in Pediatric Leukemia
Emilie Lalonde et al.
FRONTIERS IN PEDIATRICS (2017)
Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia
Amy N. Sexauer et al.
FRONTIERS IN PEDIATRICS (2017)
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches
Amanda C. Winters et al.
FRONTIERS IN PEDIATRICS (2017)
D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations
Shunsuke Yui et al.
ANNALS OF HEMATOLOGY (2017)
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Eytan M. Stein et al.
BLOOD (2017)
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis
Catherine C. Smith et al.
BLOOD (2017)
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
Muneera Al-Hussaini et al.
BLOOD (2016)
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Katherine Tarlock et al.
CLINICAL CANCER RESEARCH (2016)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Andrew M. Brunner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
Gautam Borthakur et al.
CANCER (2016)
NUP98 Fusion Proteins Interact with the NSL and MLL1 Complexes to Drive Leukemogenesis
Haiming Xu et al.
CANCER CELL (2016)
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Jessica A. Pollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Next Generation Sequencing of Acute Myeloid Leukemia: Influencing Prognosis
Asad Muhammad Ilyas et al.
BMC GENOMICS (2015)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
S. S. Kenderian et al.
LEUKEMIA (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
Sorafenib Treatment Following Hematopoietic Stem Cell Transplant in Pediatric FLT3/ITD Acute Myeloid Leukemia
Katherine Tarlock et al.
PEDIATRIC BLOOD & CANCER (2015)
Pediatric AML: From Biology to Clinical Management
Jasmijn D. E. de Rooij et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
Richard F. Schlenk et al.
BLOOD (2014)
Preclinical efficacy of MEK inhibition in Nras-mutant AML
Michael R. Burgess et al.
BLOOD (2014)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
CD4+ and CD8+T-cell reactions against leukemia-associated- or minor-histocompatibility-antigens in AML-patients after allogeneic SCT
Brigitte Steger et al.
IMMUNOBIOLOGY (2014)
Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Alan S. Gamis et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
A. Ehninger et al.
BLOOD CANCER JOURNAL (2014)
Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
Rongqing Pan et al.
CANCER DISCOVERY (2014)
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Ugo Testa et al.
BIOMARKER RESEARCH (2014)
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA
Richard F. Schlenk et al.
BLOOD (2013)
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
Paul Spear et al.
IMMUNOLOGY AND CELL BIOLOGY (2013)
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
M. Aigner et al.
LEUKEMIA (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Outcome of Pediatric Patients With Acute Myeloid Leukemia (AML) and-5/5q-Abnormalities From Five Pediatric AML Treatment Protocols: A Report From the Children's Oncology Group
Donna L. Johnston et al.
PEDIATRIC BLOOD & CANCER (2013)
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
Jessica A. Pollard et al.
BLOOD (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
Lenalidomide in AML: Del(5q) or who?
David P. Steensma et al.
BLOOD (2011)
IDH1 and IDH2 mutations in pediatric acute leukemia
A. K. Andersson et al.
LEUKEMIA (2011)
The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia
B. V. Balgobind et al.
LEUKEMIA (2011)
Leukemic Mutations in the Methylation-Associated Genes DNMT3A and IDH2 Are Rare Events in Pediatric AML: A Report From the Children's Oncology Group
Phoenix A. Ho et al.
PEDIATRIC BLOOD & CANCER (2011)
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML
Jessica A. Pollard et al.
BLOOD (2010)
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study
Brian V. Balgobind et al.
BLOOD (2009)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
Ravindra Majeti et al.
CELL (2009)
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial
Azra Raza et al.
LEUKEMIA & LYMPHOMA (2009)
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
Arthur Frankel et al.
LEUKEMIA & LYMPHOMA (2008)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Stefan Froehling et al.
CANCER CELL (2007)
Emergence of antitumor cytolytic T cells is associated with maintenance of hematologic remission in children with acute myeloid leukemia
Daniela Montagna et al.
BLOOD (2006)
Clinical implications of FLT3 mutations in pediatric AML
Soheil Meshinchi et al.
BLOOD (2006)
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML
Sohell Meshinchi et al.
BLOOD (2006)
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT Isoforms associated with human malignancies
MM Schittenhelm et al.
CANCER RESEARCH (2006)
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: Analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98
U Creutzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Death during induction therapy and first remission of acute leukemia in childhood - The St. Jude experience
JE Rubnitz et al.
CANCER (2004)
Molecules and mechanisms of the graft-versus-leukaemia effect
M Bleakley et al.
NATURE REVIEWS CANCER (2004)
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
VJN Bykov et al.
NATURE MEDICINE (2002)
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
EL Sievers et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
